Center of Tobacco Control Research, DK-5230 Odense M, Denmark.
Department of Oncology, Western University, London, ON N6A 5W9, Canada.
Int J Mol Sci. 2020 Nov 28;21(23):9054. doi: 10.3390/ijms21239054.
The aim of the review was to evaluate patient and treatment characteristics for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radioligand therapy (PRLT) associated with above-average outcome. The systematic review and meta-analysis followed recommendations by the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA). We searched for publications in PubMed, Embase, and ClinicalTrials.gov up to 31 September 2020. Thirty-six publications and four duplicates reported 2346 patients. Nearly two-thirds of the patients had bone metastases. Median overall survival (OS) was 16 months. Asymptomatic patients and patients with only lymph node metastases lived longer than symptomatic patients and patients with more extensive metastases. Patients treated with an intensified schedule of Lu PRLT lived longer than those treated with a conventional schedule. Half of the patients obtained a PSA decline ≥ 50% and these patients lived longer than those with less PSA decline. Approximately 10% of the patients developed hematologic toxicity with anemia grade 3 as the most severe adverse effect. Characteristics for patients, cancer, restaging, and PRLT predict above average overall survival following treatment with PRLT.
本次综述的目的是评估接受 PSMA 放射性配体疗法（PRLT）治疗的转移性去势抵抗性前列腺癌（mCRPC）患者的患者和治疗特征，这些患者的治疗结果优于平均水平。该系统评价和荟萃分析遵循系统评价和荟萃分析的首选报告项目（PRISMA）的建议。我们在 PubMed、Embase 和 ClinicalTrials.gov 上搜索了截至 2020 年 9 月 31 日的出版物。36 篇出版物和 4 篇重复出版物报告了 2346 名患者。近三分之二的患者有骨转移。中位总生存期（OS）为 16 个月。无症状患者和仅有淋巴结转移的患者比有症状患者和转移更广泛的患者生存期更长。接受 Lu PRLT 强化治疗方案的患者比接受常规治疗方案的患者生存期更长。大约一半的患者 PSA 下降≥50%，这些患者的生存期比 PSA 下降较少的患者更长。约 10%的患者出现血液学毒性，贫血 3 级是最严重的不良反应。患者、癌症、重新分期和 PRLT 的特征可预测接受 PRLT 治疗后总体生存期超过平均水平。
